Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab + Ipilimumab + Nivolumab in Advanced Melanoma
NCT03999749Phase 2Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Jun 2019
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in melanoma, sponsored by NYU Langone Health. Started Jun 2019; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03999749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999749.